ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The Company’s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched on 14 January 2013.
The following webpage and information therein is intended for viewing by investment audiences only. By clicking "Yes" below, you agree to be bound by the following conditions:
- The following information has been prepared by ThromboGenics NV (the "Company") and is being supplied solely to investment audiences "as is" for informational purposes only. The following information may not be further distributed or passed on to any other person or published or reproduced, in whole or in part, by any medium or in any form for any purpose. All numerical data contained in the following information has been derived from ThromboGenics’ consolidated financial statements.
- No representation or warranty, expressed or implied, is or will be made as to, and no reliance should be placed on, the fairness, accuracy, completeness, or correctness of the following information or opinions contained therein. The following information may be subject to updating, completion, revision, verification, and amendment, and such information may change materially. The Company is under no obligation to update or keep current the following information and any opinions expressed within are subject to change without notice. None of the Company or any of its affiliates, its advisors, or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of the following information or its contents or otherwise arising in connection with such information.
- The following information does not constitute investment advice, and shall not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
Do you accept and agree to be bound by the above conditions?
